Patients treated with Gilenya “show benefits”

[MSUK]

New research evaluating Gilenya’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) has largely supported its use, finding the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies...Read more - http://www.ms-uk.org/MSnews

[CureOrBust]

..following 105 RRMS patients...
finding the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies....
The efficacy and safety results of this study were found to be comparable to those observed in Phase 3 clinical trials...

So, it basically performs the same as what the much larger Phase 3 clinical trial found, ie no news. I think the manufacturers "spin doctors" had a hand in this to keep Gylenya in the "news" and on the prescription pad.

Sure, its great that it is being monitored, but hardly news.